Natural History of Merkel Cell Carcinoma Following Locoregional Recurrence

Abstract

Locoregional recurrence is a substantial problem in patients with MCC and is a poor prognostic sign. In those patients who experience a locoregional recurrence, aggressive efforts to regain locoregional control appear warranted and may result in long-term survival.

15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma

“…An overall 5-y survival rate of about 60% for all stages of MCC combined has been reported (3), and our institution has reported an estimated 45% 5-y rate in patients with stage I-III MCC (14). Cases of successful salvage have been reported in studies in which patients had locoregional recurrent disease and received multimodality treatment (15,16).…”

Multiple Merkel cell carcinomas: Late metastasis or multiple primary tumors? A molecular study

“…MCC has a high propensity for local recurrence, with a median time between diagnosis and recurrence of 6 months 4 . We present a case of a 79-year-old woman who initially presented with 2 MCCs of the nasal bridge and left arm, followed by a third MCC on the right nose 8 years later.…”

Poly ADP‐ribose polymerase‐1 as a potential therapeutic target in Merkel cell carcinoma

“…Although the majority of patients with Merkel cell carcinoma present with local disease amenable to surgery and/or radiotherapy, tumor recurrence occurs in at least 35% of the cases . Patients with stage IV disease have a dismal prognosis with a 5‐year survival ranging from 0%‐18% .…”

“…Although the majority of patients with Merkel cell carcinoma present with local disease amenable to surgery and/or radiotherapy, tumor recurrence occurs in at least 35% of the cases. 3 Patients with stage IV disease have a dismal prognosis with a 5-year survival ranging from 0%-18%. 4 Given its histological similarities with small cell lung cancer (SCLC), the combination of platinum and etoposide or single-agent topotecan are frequently used to treat patients with incurable disease.…”